A246960 Stock Overview
SCL Science Inc., engages in the development and sale of medical sealant products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SCL Science Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,730.00 |
| 52 Week High | ₩10,770.00 |
| 52 Week Low | ₩6,750.00 |
| Beta | 0.98 |
| 1 Month Change | 4.55% |
| 3 Month Change | 8.99% |
| 1 Year Change | 28.38% |
| 3 Year Change | -38.52% |
| 5 Year Change | -47.09% |
| Change since IPO | -54.88% |
Recent News & Updates
Shareholder Returns
| A246960 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -0.8% | -0.2% | 2.1% |
| 1Y | 28.4% | 27.6% | 6.6% |
Return vs Industry: A246960 matched the KR Medical Equipment industry which returned 27.6% over the past year.
Return vs Market: A246960 exceeded the KR Market which returned 6.6% over the past year.
Price Volatility
| A246960 volatility | |
|---|---|
| A246960 Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A246960 has not had significant price volatility in the past 3 months.
Volatility Over Time: A246960's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 24 | Moonsue Lee | www.innotherapy.com |
SCL Science Inc., engages in the development and sale of medical sealant products in South Korea. The company’s products include InnoSEAL, an externally applied hemostatic agent; InnoSEAL Plus, an absorbable hemostatic pad; EndoSil, an absorbable hemostatic agent used for the gastrointestinal oozing bleeding; GellySil, a biomaterial and the proprietary material product. It also provides Film-type surgical sealant to complete sealing of anastomosis site; STOP needle, a self-sealing needle for general and ophthalmic use; wound dressing used for chronic wounds, burns, etc.; and Gene therapy, a bio-therapeutics delivery system.
SCL Science Inc. Fundamentals Summary
| A246960 fundamental statistics | |
|---|---|
| Market cap | ₩63.55b |
| Earnings (TTM) | -₩5.03b |
| Revenue (TTM) | ₩1.32b |
48.1x
P/S Ratio-12.6x
P/E RatioIs A246960 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A246960 income statement (TTM) | |
|---|---|
| Revenue | ₩1.32b |
| Cost of Revenue | ₩1.11b |
| Gross Profit | ₩208.41m |
| Other Expenses | ₩5.23b |
| Earnings | -₩5.03b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -690.52 |
| Gross Margin | 15.76% |
| Net Profit Margin | -380.17% |
| Debt/Equity Ratio | 41.0% |
How did A246960 perform over the long term?
See historical performance and comparison